Search
Filters
Clear All
  • 9
  • 39
  • 2
  • 561

Phase

  • 9
  • 8
  • 36
  • 8
  • 46
  • 6
  • 470
  • 553
  • 284

Found 611 in-health trials

A listing of in-health medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors

P
Patrick Loehrer, MD
18-100 years
All genders
In an unbiased CRISPR screen, RIPK1 was identified as a top gene contributing to immunotherapy resistance. In addition, RIPK1 has been reported to drive pancreatic oncogenesis. In murine models, inhibition of RIPK1 kinase activity in the pancreatic tumor microenvironment leads to the replacement of tumor-permissive myeloid infiltrates with innate cells …
Learn More

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600E Mutations

S
Sandeep Batra, MD
3-25 years
All genders
This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in treating participants with newly diagnosed malignant glioma without H3 K27M or BRAFV600E mutations.
Learn More

Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)

U
Utpal Dave, MD
18-100 years
All genders
The purpose of this study is to test the safety and efficacy of combining two drugs, ixazomib and romidepsin. It will also measure the percentage of patients whose tumor completely resolves after receiving ixazomib and romidepsin.
Learn More

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)

B
Bryan Schneider, MD
18 years and older
All genders
Phase 2
Interventional
This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease afterve therapy will be assigned to 1 of 3 Arms based on plasma ctDNA positivity and genomic marker(s).
Learn More

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

S
Shadia Jalal, MD
18-100 years
All genders
This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery.
Learn More

A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor

G
Greg Durm, MD
18-100 years
All genders
This is a single-arm phase II study of continuation immunotherapy with pembrolizumab following initial benefit with a PD-1 or PD-L1 inhibitor.
Learn More

Evaluation of an Exercise intervention for Vincristine induced peripheral neuropathy in pediatric cancer patients

J
Jamie Renbarger, MD
100 years and younger
All genders
The purpose of this study is to evaluate the feasibility and acceptability of exercise as an intervention for vincristine-induced peripheral neuropathy in pediatric patients with ALL.
Learn More

Title: A Phase 2 multicenter open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS) non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS)

K
Kristy Pilbeam
1-18 years
All genders
The purpose of this study is to assess of activity of eribulin mesylate in pediatric subjects with relapsed/refractory RMS, NRSTS or EWS.
Learn More

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases in Children and Young Adults With Refractory Sarcomas Wilms Tumor and Other Rare Tumors

S
Sandeep Batra, MD
2-30 years
All genders
This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed.
Learn More

A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement

S
Sandeep Batra, MD
1 years and younger
All genders
This pilot phase II trial studies the side effects of azacitidine and combination chemotherapy in infants with acute lymphoblastic leukemia and KMT2A gene rearrangement.
Learn More
571 - 580 of 611